NVDA
NVIDIA
-- 134.250 AVGO
Broadcom
-- 224.800 TSLA
Tesla
-- 436.230 PLTR
Palantir
-- 76.070 AMD
Advanced Micro Devices
-- 126.910 
NEWS
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Thursday, 5th December at 6:45 am
– Covers cGMP manufacturing processes –
– Expected to provide protection until April 29, 2040 –
MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that the European Patent Office has issued a Notice of Allowance for a new patent application (European Patent Appl. No. 20798130.9) covering key aspects of the Company's allogeneic, off-the-shelf ThermoStem® metabolic disease platform.
Claims granted under the new patent cover a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.
Thursday, 5th December at 6:45 am
– Covers cGMP manufacturing processes –
– Expected to provide protection until April 29, 2040 –
MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that the European Patent Office has issued a Notice of Allowance for a new patent application (European Patent Appl. No. 20798130.9) covering key aspects of the Company's allogeneic, off-the-shelf ThermoStem® metabolic disease platform.
Claims granted under the new patent cover a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.
In May 2024, BioRestorative announced the development of a novel exosome-based biologic program targeting obesity, advising that the Company plans to initiate the formal U.S. Food and Drug Administration (FDA) process for this ThermoStem ® -based therapeutic candidate by filing a Drug Master File (DMF). On the heels of that announcement, BioRestorative reported that it had begun to engage in substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a potential license of BioRestorative's allogeneic, off-the-shelf ThermoStem® metabolic intellectual property. Those discussions are continuing; however, no assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment